Ionis drops after forecasting 2026 revenue below expectations

Ionis Pharmaceuticals

25/02/2026 12:37

** Shares of drugmaker Ionis Pharmaceuticals IONS.O fall 6.4% to $80 premarket

** Co forecasts 2026 revenue between $800 million and $825 million, below analysts' average expectation of $902 million

** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter

** Co reports Q4 loss of $1.41/shr vs analysts' average loss estimate of $1.32/shr

** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million

** Up to last close, stock up 8% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))